Cite

HARVARD Citation

    Hézode, C. et al. (2017). Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver international. pp. 1304-1313. [Online]. 
  
Back to record